Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy

International Journal of Molecular Medicine

Volumn 23, Issue 3, 2009, Pages 407-413

  Rao, Myneni Venkatasatya Srinivas ^a   Berk, Jason ^a   Goodloe III, Saud Abdulaziz Almojaly Samuel ^a   Margarone III, Joseph ^a   Sullivan, Maureen ^a   Dziak, Rosemary ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bisphosphonates; Osteoblasts; Osteonecrosis; Parathyroid hormone; Platelet derived growth factor; Vitamin D

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; PARATHYROID HORMONE; PLATELET DERIVED GROWTH FACTOR BB; THYMIDINE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; DIFFERENTIATION ANTIGEN; IMIDAZOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; VITAMIN D;

ADULT; AGED; ALVEOLAR BONE; ARTICLE; BONE REMODELING; BREAST CANCER; CANCER PATIENT; CASE REPORT; CELL ASSAY; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; OSTEOBLAST; PRIORITY JOURNAL; TREATMENT DURATION; BIOSYNTHESIS; BONE REGENERATION; BREAST TUMOR; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; ANTIGENS, DIFFERENTIATION; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; BREAST NEOPLASMS; CALCITRIOL; CELL DIFFERENTIATION; CELLS, CULTURED; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOBLASTS; PARATHYROID HORMONE; PLATELET-DERIVED GROWTH FACTOR; VITAMIN D;

EID: 64249137913     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000145     Document Type: Article

References (35)

1. Silverman SL and Maricic M: Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 37: 1-12, 2007.
2. Woo SB, Hellstein JW and Kalmar JR: Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761, 2006.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ and Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534, 2004.
4. Pazianas M, Miller P, Blumentals WA, Bernal M and Kothawala P: A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29: 1548-1558, 2007.
5. Polizzotto MN, Cousins V and Schwarer AP: Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 132: 114, 2006.
6. Etminan M, Aminzadeh K, Matthew IR and Brophy JM: Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35: 691-695, 2008.
7. Reinholz GG, Getz B, Pederson L, et al: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60: 6001-6007, 2000.
8. Hellstein JW and Marek CL: Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63: 682-689, 2005.
9. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, et al: Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8: 1080-1084, 2002.
10. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, et al: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893-2897, 2003.
11. Plumb JA: Cell sensitivity assays: the MTT assay. Methods Mol Med 88: 165-169, 2004.
12. Perinpanayagam H, Martin T, Mithal V, Dahman M, Marzec N, Lampasso J and Dziak R: Alveolar bone osteoblast differentiation and Runx2/Cbfa1 expression. Arch Oral Biol 51: 406-415, 2006.
13. Lampasso JD, Marzec N, Margarone J III and Dziak R: Role of protein kinase C alpha in primary osteoblastic cell proliferation. J Bone Miner Res 17: 1968-1976, 2002.
14. Canalis E, McCarthy TL and Centrella M: Growth factors and the regulation of the bone remodeling. J Clin Invest 81: 277-281, 1988.
15. Centrella M, McCarthy TL and Canalis E: Platelet-derived growth factor enhances deoxyribonucleic acid and collagen synthesis in osteoblast-enriched cultures from fetal rat parietal bone. Endocrinology 125: 13-19, 1989.
16. Centrella M, McCarthy TL, Kusmik WF and Canalis E: Isoform-specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone. J Clin Invest 89: 1076-1084, 1992.
17. Lynch SE, Williams RC, Polson AM, Howell TH, Reddy MS, Zappa UE and Antoniades HN: A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. J Clin Periodontol 16: 545-548, 1989.
18. Park JB, Matsuura M, Han KY, Norderyd O, Lin WL, Genco RJ and Cho MI: Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. J Periodontol 66: 462-477, 1995.
19. Cho MI, Liu WL and Genco RJ: Platelet-derived growth factor-mediated guided tissue regenerative therapy. J Periodontol 66: 522-530, 1995.
20. Giannobile WV, Hernandez RA, Finkelman RD, Ryan S, Kiritsy CP, D'Andrea M and Lynch SE: Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in Macaca fasciculars. J Periodont Res 31: 301-312, 1996.
21. Anusaksathien O, Jin Q, Zhao M, Somerman MJ and Giannobile WV: Effect of sustained gene delivery of platelet-derived growth factor or its antagonist (PDGF-1308) on tissue-engineered cementum. J Periodontol 75: 429-440, 2004.
22. Nevins M, Camelo M, Nevins ML, Schenk RK and Lynch SE: Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. J Periodontol 74: 1282-1292, 2003.
23. Adornato MC, Motcos I and Rozanski J: The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. JADA 138: 971-977, 2007.
24. Curi MM, Cossolin GSI, Koga DH, Araujo SR, Feber O, dos Santos MO and Zardetto C: Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasms: Report of 3 cases. J Oral Maxillofac Surg 65: 349-355, 2007.
25. Holick MF: The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 4: 96-102, 2006.
26. Manolagas SC, Burton DW and Deftos LJ: 1,25-Dihydroxy-vitamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem 256: 7115-7117, 1981.
27. Chavassieux P, Boivin G, Terrier C, Serre CM, Lagarde D and Meunier PJ: Effects of 1,25 dihydroxyvitamin D3 on the morphology and alkaline phosphatase activity of ROS 17/2,8 osteoblastic cells: influence of time and dose. Reprod Nutr Dev 30: 439-443, 1990.
28. Wang DA, Miura M, Demura H and Sato K: Anabolic effects of 1,25-Dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology 138: 2953-2962, 1997.
29. Sou H, Koike M, Elstner E, Cambell M, Le J, Uskokovic MR, Kamada N and Koeffler HP: 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998.
30. Zhang X, Nicosia SV and Bai W: Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets 6: 229-244, 2006.
31. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer Res 26: 2515-2524, 2006.
32. Badros A, Goloubrva O, Terpos E, et al: Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 1: 1-3, 2008.
33. Ardine M, Generali D, Donadio M, et al: Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 17: 1336-1337, 2006.
34. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 17: 2094-2105, 2002.
35. Harper RP and Fung E: Resolution of bisphosphonate associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65: 573-580, 2007.